research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-24. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
intermediates in biosynthesis, in post-translational formation of proteins, in a physiological role (e.g. components of bacterial cell walls, neurotransmitters and toxins), natural or man-made pharmacological compounds, present in meteorites or used in prebiotic experiments (such as the Miller–Urey experiment), might be important neurotransmitters, such as γ-aminobutyric acid, and can play a crucial role in cellular bioenergetics, such as creatine.
In fluid dynamics, the Darcy–Weisbach equation is an empirical equation that relates the head loss, or pressure loss, due to viscous shear forces along a given length of pipe to the average velocity of the fluid flow for an incompressible fluid. The equation is named after Henry Darcy and Julius Weisbach. Currently, there is no formula more accurate or universally applicable than the Darcy–Weisbach supplemented by the Moody diagram or Colebrook equation. The Darcy–Weisbach equation contains a dimensionless friction factor, known as the Darcy friction factor. This is also variously called the Darcy–Weisbach friction factor, friction factor, resistance coefficient, or flow coefficient.
Information about the maximum size of the clown loach varies, with some estimates ranging up to 20–30 cm (7.9–11.8 in), and with typical adult sizes ranging from 15–20 cm (5.9–7.9 in). The fish's body is long and laterally compressed, with an arched dorsal surface and a flat ventral surface. Its head is relatively large and its mouth faces downward with thick, fleshy lips, and four pairs of barbels. The barbels on the lower jaw are small and difficult to see. Clown loaches can make clicking sounds when they are happy, being territorial (used as a type of weapon/warning) or mating. This sound is produced by the grinding of their pharyngeal teeth. The body is whitish-orange to reddish-orange, with three thick, black, triangular, vertical bands. The anterior band runs from the top of the head and through the eye, the medial band lies between the head and the dorsal fin, and wraps around to the ventral surface, and the posterior band covers almost all of the caudal peduncle and extends to the anal fin. There is some regional colour variation within the species; the pelvic fins on fish from Borneo are reddish-orange and black, while the pelvic fins on fish from Sumatra are entirely reddish-orange. The fish is sexually dimorphic, with females being slightly plumper than males. In addition, the tips of the tail on the male curve inwards slightly, whereas the females have straight tips. The fish has a movable spine that lies in a groove below the eye, which may be extended as a defence mechanism. The spine may cause a painful wound, but is not venomous.
Toxicology Association); Ralph DeFronzo (medicine, Yale); Kurt Dubowski (forensic pathology, University of Oklahoma); Daniel Foster (medicine, University of Texas); Daniel Furst, (medicine, University of Iowa); Harold Lebovitz (director of clinical research, State University of New York); Vincent Marks (clinical biochemistry, Surrey, vice-president Royal College of Pathologists and president, Association of Clinical Biochemistry); and Arthur Rubinstein (medicine, University of Chicago). Other experts testified that the hypodermic needle tainted with insulin on the outside (but not inside) would have been dipped in insulin but not injected (injecting it in flesh would have wiped it clean). Evidence also showed that her hospital admission three weeks before the final coma showed she had ingested at least 73 aspirin tablets, a quantity that could only have been self-administered, and which indicated her state of mind. Cahill recanted his testimony from the first trial and opined that insulin was the most reasonable explanation for von Bülow's coma, but that "neither he nor anyone else could ever be 100 percent certain of the cause of the comas."
"RCSB Protein Data Bank - Structure Summary for 1Z7C - Crystal Structure of Human Placental Lactogen". "Human Chorionic Somatomammotropin Enhancer Function Is Mediated by Cooperative Binding of TEF-1 and CSEF-1 to Multiple, Low-Affinity Binding Sites". Archived from the original on 2008-07-05.
Sources: en.wikipedia.org
== History == Orthologs of AgRP, ASIP, MCIR, and MC4R have been found in mammalian, teleost fish, and avian genomes. This suggests that the agouti-melanocortin system evolved by gene duplication from individual ligand and receptor genes in the last 500 million years.
MacDonald et al. (1990) has described four general community types. These are communities dominated by Vestimentiferan tube worms (Lamellibrachia c.f. barhami and Escarpia spp.), mytilid mussels (Seep Mytilid Ia, Ib, and III, and others), vesicomyid clams (Vesicomya cordata and Calyptogena ponderosa), and infaunal lucinid or thyasirid clams (Lucinoma sp. or Thyasira sp.). Bacterial mats are present at all sites visited to date. These faunal groups tend to display distinctive characteristics in terms of how they aggregate, the size of aggregations, the geological and chemical properties of the habitats in which they occur, and, to some degree, the heterotrophic fauna that occur with them. Many of the species found at these cold seep communities in the Gulf of Mexico are new to science and remain undescribed. Individual lamellibrachid tube worms, the longer of two taxa found at seeps, can reach lengths of 3 metres (9.8 feet) and live hundreds of years (Fisher et al., 1997; Bergquist et al., 2000). Growth rates determined from recovered marked tube worms have been variable, ranging from no growth of 13 individuals measured one year to a maximum growth of 9.6 cm/yr (3.8 in/yr) in a Lamellibrachia individual (MacDonald, 2002). Average growth rate was 2.19 cm/yr (0.86 in/yr) for the Escarpia-like species and 2.92 cm/yr (1.15 in/yr) for lamellibrachids. These are slower growth rates than those of their hydrothermal vent relatives, but Lamellibrachia individuals can reach lengths 2–3 times that of the largest known hydrothermal vent species. Individuals of Lamellibrachia sp.
== Hazards == Old vacuum-pump oils that were produced before circa 1980 often contain a mixture of several different dangerous polychlorinated biphenyls (PCBs), which are highly toxic, carcinogenic, persistent organic pollutants.
Metabolism of glucose produces ATP, which increases the ATP to ADP ratio. The KATP channels close when the ATP to ADP ratio rises. The closure of the KATP channels causes the outward potassium ion current to diminish, leading to inward currents of potassium ions dominating. As a result, the potential difference across the membrane becomes more positive (as potassium ions accumulate inside the cell). This change in potential difference opens the voltage-gated calcium channels, which allows calcium ions from outside the cell to move into the cell down their concentration gradient. When the calcium ions enter the cell, they cause vesicles containing insulin to move to, and fuse with, the cell surface membrane, releasing insulin by exocytosis into the pancreatic capillaries. The venous blood then eventually empties into the hepatic portal vein. In addition to the triggering pathway, the amplifying pathway can cause increased insulin secretion without a further increase in intracellular calcium levels. The amplifying pathway is modulated by byproducts of glucose metabolism along with various intracellular signaling pathways; incretin hormone signaling being one important example.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.